TLX101 for Brain Cancer IPAX-1 Study Update
Telix Pharmaceuticals has released an update on the progress of its TLX101 product in the treatment of glioblastoma...
Read more
Latest News
Category: Clinical
Telix Pharmaceuticals has released an update on the progress of its TLX101 product in the treatment of glioblastoma...
Read more
Telix Pharmaceuticals Limited is pleased to release a Clinical Trial Program Update for Q3,...
Read more
Telix Pharmaceuticals Limited is pleased to announce the completion of a Clinical Trial Notification (CTN) review for a Phase I/II study for TLX250-CDx (89Zr-girentuximab) in...
Read more
Telix Pharmaceuticals Limited is pleased to announce that the first Australian patient has been added to the Phase III ZIRCON study. The first Australian patient was dosed with TLX250-CDx at...
Read more
Telix has just launched an information site on our illumet™ prostate cancer imaging product. The website provides an informative depository about how the product works and its potential in clinical...
Read more
Telix Pharmaceuticals Limited today announced a strategy update for the TLX591 (prostate therapy)...
Read more
Telix Pharmaceuticals has today announced a clinical collaboration with Radboud University Medical...
Read more
Telix has today announced a collaboration with Memorial Sloan Kettering Cancer Center...
Read more
Telix Pharmaceuticals is pleased to announce that it has entered into a development and commercialisation partnership with Advanced Nuclear Medicine Ingredients SA...
Read more
Telix is pleased to announce that it has entered into a technology licensing agreement and a research collaboration agreement with the University of...
Read more